Open Science for Children’s Health
M4K Pharma is using open science to revolutionize how affordable new treatments are discovered and developed. Through our Medicines4Kids program, we are aggregating and aligning the work of global academics, foundations and pharma/biotech researchers to advance new cures for childhood diseases not well served by current business models.
M4K Pharma’s first program is the discovery, development and commercialization of an ALK2 enzyme inhibitor which will provide the first therapeutic developed specifically for the treatment of Diffuse Intrinsic Pontine Glioma (DIPG).
M4K Pharma’s Data:
In line with M4K Pharma’s open science principles, we are committed to sharing our research data freely in the public domain. Our data is currently available for public viewing in the video recordings of our monthly open scientific updates, which are posted to our Blog and also available through our YouTube Channel.
Latest Blog Posts
Sept 2020 M4K Pharma Open Scientific Update Meeting – Recording
Listen to a recording of the September 2020 Scientific Update Meeting Listen to M4K Pharma’s Scientific Update Meeting from September 23rd, 2020 where our scientists and collaborators discuss the latest progress in [...]
Childhood brain tumours: From tissue samples to new treatment options
In a piece to mark Childhood Cancer Awareness Month, Dr. Diana Martins Carvalho reflects on the vital support of families who generously donate tissue samples and funds that enable her research into childhood brain tumours. [...]
M4K Team publishes in the Journal of Medicinal Chemistry
M4K Team publishes in the Journal of Medicinal Chemistry In the May and September 2020 issues of the Journal of Medicinal Chemistry, the M4K team and collaborators published two articles on M4K's open science approach [...]
Partners
